Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV F Subunit Vaccine in Healthy Adults
NCT02298179Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) (12 arms), sponsored by GSK. Primary endpoints: Geometric Mean Titers of Serum Anti-RSV Neutralizing Antibody Titers at Day 57, Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers at Day 57 and 4 more. Started Dec 2014; status: completed.
02
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02298179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298179.